A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies

The University of Chicago

Status and phase: Completed; Phase 1

Conditions: Genital Neoplasms, Female

Treatments: Drug: Topotecan; Drug: CCI-779 (temsirolimus)

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00523432

15424A

Details and patient eligibility

About

The aim of the trial is to determine the recommended phase II dose of weekly intravenous topotecan in combination with a fixed dose (25 mg or 15 mg) of weekly intravenous temsirolimus in patients with and without prior pelvic radiation.

Enrollment: 15 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically confirmed recurrent or metastatic ovarian carcinoma, fallopian tube carcinoma, primary peritoneal carcinoma, cervical carcinoma, endometrial carcinoma, vulvar carcinoma, vaginal carcinoma, or carcinosarcoma of the ovary, endometrium or cervix.

• Prior Therapy: at least one and may have up to three prior cytotoxic chemotherapeutic regimens for the management of primary disease.

• Must be at least 18 years of age.

• GOG performance status must be 0 or 1.

• Patients must have adequate organ and marrow function as defined below:

  • hemoglobin ≥10g/dL
  • absolute neutrophil count ≥1,500/uL
  • platelets ≥100,000/uL
  • total bilirubin below the institutional upper limit of normal
  • AST(SGOT)/ALT(SGPT) below the institutional upper limit of normal
  • creatinine below the institutional upper limit of normal
  • cholesterol ≤ 350 mg/dL (fasting)
  • triglycerides ≤ 400 mg/dL (fasting)
  • albumin ≥ 3.0 mg/dL

• negative pregnancy test for women able to have children

• Ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

• Prior therapy with topotecan
• More than 3 prior cytotoxic chemotherapeutic regimens or treatment with temsirolimus or any other mTOR inhibitor
• Concomitant hormonal therapy or radiation therapy
• Clinically significant infections or other medical problems of significant severity
• History of unstable angina or myocardial infarction within the past six months
• Known brain metastases unless the metastases have been controlled by prior surgery or radiotherapy, and the patient has been neurologically stable and off of steroids for at least 4 weeks.
• Any requirement for oxygen
• Cannot be receiving potent enzyme-inducing antiepileptic drugs (EIAEDs; e.g., phenytoin, carbamazepine, phenobarbital) nor any other potent CYP3A4 inducer such as rifampin or St. John's wort, as these may decrease temsirolimus levels. Use of agents that potently inhibit CYP3A4 (and hence may raise temsirolimus levels), such as ketoconazole, is discouraged, but not specifically prohibited.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Factorial Assignment

Masking: None (Open label)

---

15 participants in 2 patient groups

A

Experimental group

Description:

Arm A will consist of subjects without prior pelvic radiation or with radiation to a field smaller than the whole pelvis. Subjects will receive weekly CCI-779 and topotecan at the assigned dose.

Treatment:

Drug: Topotecan

Drug: CCI-779 (temsirolimus)

B

Experimental group

Description:

Arm A will consist of subjects with prior whole pelvic radiation. Subjects will receive weekly CCI-779 and topotecan at the assigned dose.

Treatment:

Drug: Topotecan

Drug: CCI-779 (temsirolimus)